These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10740120)

  • 1. Challenges in the conduct and interpretation of phase II (pilot) randomized trials.
    Yusuf S
    Am Heart J; 2000 Apr; 139(4):S136-42. PubMed ID: 10740120
    [No Abstract]   [Full Text] [Related]  

  • 2. Sample size and interim analysis issues for dose selection.
    Lee KL
    Am Heart J; 2000 Apr; 139(4):S161-5. PubMed ID: 10740124
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials.
    O'Connor CM; Gattis WA; Ryan TJ
    Am Heart J; 2000 Apr; 139(4):S143-54. PubMed ID: 10740121
    [No Abstract]   [Full Text] [Related]  

  • 4. Design and interpretation of equivalence trials.
    Fleming TR
    Am Heart J; 2000 Apr; 139(4):S171-6. PubMed ID: 10740126
    [No Abstract]   [Full Text] [Related]  

  • 5. Equivalence and noninferiority trials.
    Siegel JP
    Am Heart J; 2000 Apr; 139(4):S166-70. PubMed ID: 10740125
    [No Abstract]   [Full Text] [Related]  

  • 6. False positive rates of randomized phase II designs.
    Liu PY; LeBlanc M; Desai M
    Control Clin Trials; 1999 Aug; 20(4):343-52. PubMed ID: 10440561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical research design in cardiology: learning the right lessons too well: observations and recommendations from the Cardiovascular Cell Therapy Research Network (CCTRN).
    Hare JM; Bolli R; Cooke JP; Gordon DJ; Henry TD; Perin EC; March KL; Murphy MP; Pepine CJ; Simari RD; Skarlatos SI; Traverse JH; Willerson JT; Szady AD; Taylor DA; Vojvodic RW; Yang PC; Moyé LA;
    Circulation; 2013 Apr; 127(15):1630-5. PubMed ID: 23588961
    [No Abstract]   [Full Text] [Related]  

  • 8. Estimating the distribution of quality-adjusted life with censored data.
    Tsiatis AA
    Am Heart J; 2000 Apr; 139(4):S177-81. PubMed ID: 10740127
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II dose-response trials: A simulation study to compare analysis method performance under design considerations.
    Rekowski J; Köllmann C; Bornkamp B; Ickstadt K; Scherag A
    J Biopharm Stat; 2017; 27(5):885-901. PubMed ID: 28362145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the sample size for a t-test using an internal pilot.
    Denne JS; Jennison C
    Stat Med; 1999 Jul; 18(13):1575-85. PubMed ID: 10407230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
    Sambucini V
    J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seamless Phase II/III combination study through response adaptive randomization.
    Wang L; Cui L
    J Biopharm Stat; 2007; 17(6):1177-87. PubMed ID: 18027224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations.
    Butler J; Hamo CE; Udelson JE; O'Connor C; Sabbah HN; Metra M; Shah SJ; Kitzman DW; Teerlink JR; Bernstein HS; Brooks G; Depre C; DeSouza MM; Dinh W; Donovan M; Frische-Danielson R; Frost RJ; Garza D; Gohring UM; Hellawell J; Hsia J; Ishihara S; Kay-Mugford P; Koglin J; Kozinn M; Larson CJ; Mayo M; Gan LM; Mugnier P; Mushonga S; Roessig L; Russo C; Salsali A; Satler C; Shi V; Ticho B; van der Laan M; Yancy C; Stockbridge N; Gheorghiade M
    Circ Heart Fail; 2017 Apr; 10(4):. PubMed ID: 28356300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An FDA perspective on antiarrhythmic drugs in phase II trials.
    Lipicky R
    Am Heart J; 2000 Apr; 139(4):S197-9. PubMed ID: 10740131
    [No Abstract]   [Full Text] [Related]  

  • 15. Using the partitioning principle to adaptively design dose-response studies.
    Ling X; Hsu J
    J Biopharm Stat; 2006; 16(5):733-43. PubMed ID: 17037268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating a sequence of randomized phase II trials to discover promising treatments.
    Strauss N; Simon R
    Stat Med; 1995 Jul; 14(13):1479-89. PubMed ID: 7481186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
    Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
    Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formal statistical testing and inference in randomized phase II trials in medical oncology.
    Saad ED; Sasse EC; Borghesi G; Miranda VC; Fede AB; Saad LS; Oliveira V; Barros EA; Pascoin M; Del Giglio A; Riechelmann R
    Am J Clin Oncol; 2013 Apr; 36(2):143-5. PubMed ID: 22307212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A three-outcome design for randomized comparative phase II clinical trials.
    Hong S; Wang Y
    Stat Med; 2007 Aug; 26(19):3525-34. PubMed ID: 17262879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic end points in phase II trials.
    Mark DB; Simons TA
    Am Heart J; 2000 Apr; 139(4):S155-7. PubMed ID: 10740122
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.